People who brought their blood sugar back to normal after a prediabetes diagnosis cut their risk of cardiovascular death or hospitalization for heart failure by 58 percent, according to post-hoc analyses of two landmark prevention trials spanning decades and two continents. The findings, drawn from the U.S. Diabetes Prevention Program Outcomes Study and the Da Qing Diabetes Prevention Outcome Study in China, show that prediabetes remission, defined as fasting glucose below 100 mg/dL or HbA1c under 5.7 percent, tracked with an adjusted hazard ratio of roughly 0.42 for a composite cardiovascular endpoint. For the roughly one in three American adults living with prediabetes, the data point toward a measurable, achievable target that could sharply reduce the chance of a fatal heart event.
Why returning to normal blood sugar protects the heart
Prediabetes has long been treated as a warning sign for type 2 diabetes, but its direct connection to heart disease has received less clinical attention. These new analyses shift that framing. Participants who achieved and maintained normal glucose levels did not simply delay diabetes; they experienced a 42 percent lower risk of heart attack, stroke, and other major adverse cardiovascular events, according to a summary from King’s College. The cardiovascular benefit appeared whether participants had originally been assigned to a lifestyle intervention group or a control arm, suggesting that glucose normalization itself, rather than any single trial treatment, drove the protective effect.
One plausible explanation centers on what chronically elevated blood sugar does to blood vessels. Sustained hyperglycemia damages the endothelium, the thin layer of cells lining arteries, and accelerates arterial stiffness. Excess glucose also promotes low-grade inflammation and oxidative stress, which can destabilize plaque in coronary arteries. Returning to normoglycemia may interrupt those processes through pathways that operate at least partly independently of weight loss or changes in cholesterol.
Both the DPPOS and Da Qing cohorts collected serial biomarker and clinical data over years of follow-up, which gives researchers the raw material to test whether improvements in vascular function track with glucose normalization even after adjusting for body weight and lipid levels. That question has not yet been fully answered, but the size of the cardiovascular risk reduction, 58 percent for the most severe outcomes, suggests the mechanism is not trivial. It also reinforces the idea that “borderline” blood sugar elevations are not benign, and that moving from prediabetes back to normal is more than a cosmetic change on a lab report.
Two trials, three decades, and a consistent signal
The strength of the evidence rests on the depth and duration of the two source trials. The Da Qing study enrolled adults with impaired glucose tolerance in China beginning in the 1980s and tracked them for three decades, making it one of the longest-running lifestyle intervention studies ever conducted. Participants were randomized to diet, exercise, or combined lifestyle changes, and the original trial demonstrated that these interventions reduced the incidence of diabetes. The 30-year outcome data extended those findings to hard cardiovascular endpoints, including cardiovascular death, showing that early lifestyle changes carried benefits well into later life.
The DPPOS, run through the National Institute of Diabetes and Digestive and Kidney Diseases, began as a follow-on to the original U.S. Diabetes Prevention Program and has continued to collect outcome data on its participants for more than two decades. The recent post-hoc work, described in a Lancet analysis, combined data from both trials to ask a question neither was originally designed to answer: does returning to normal blood sugar after prediabetes reduce the risk of heart problems? The adjusted hazard ratio of approximately 0.42 for the composite cardiovascular endpoint, encompassing cardiovascular death and heart failure hospitalization, provided a clear affirmative signal.
Across the two cohorts, the pattern was consistent despite major differences in geography, health systems, and baseline diet and activity levels. Da Qing participants were treated in a largely hospital-based Chinese system in the late 20th century, while DPPOS participants were managed in U.S. clinical settings with evolving standards of cardiovascular care. Yet in both, those who achieved remission saw substantially fewer serious heart-related outcomes than those who remained in the prediabetic range or progressed to diabetes. That convergence strengthens the argument that the observed benefit is not just an artifact of one trial’s design or one country’s medical practices.
Remission in these analyses was defined by straightforward clinical thresholds: fasting glucose below 100 mg/dL or HbA1c below 5.7 percent, without the use of glucose-lowering medication. Those are numbers any primary care physician can check with a routine blood draw, which makes the finding immediately actionable in clinical practice. Clinicians do not need advanced imaging or specialized biomarkers to identify patients who have moved out of the danger zone; standard lab panels suffice.
What this means for patients and clinicians
For people living with prediabetes, the message is both sobering and hopeful. On one hand, the data underscore that prediabetes is not a harmless label. It carries a real, measurable increase in cardiovascular risk, even before full-blown diabetes develops. On the other hand, the same data show that risk is modifiable. Bringing blood sugar back to normal levels, and keeping it there, may cut the chance of dying from a heart problem or being hospitalized for heart failure by more than half.
In practical terms, that shifts the clinical conversation. Instead of merely warning patients that they are “on the road” to diabetes, clinicians can frame remission of prediabetes as a concrete goal with clear cardiovascular payoffs. Lifestyle changes such as increased physical activity, dietary adjustments that reduce refined carbohydrates, modest weight loss, and smoking cessation remain the first-line tools. For some patients, especially those with multiple risk factors, clinicians may also consider early pharmacologic strategies, though the remission definition in these analyses did not rely on glucose-lowering drugs.
Importantly, the findings also suggest that partial improvements may not confer the same protection as full remission. Patients whose blood sugar levels improved but remained in the prediabetic range did not see as large a reduction in cardiovascular events as those who crossed back into normal territory. That nuance argues for setting ambitious but realistic targets and following up regularly to see whether interventions are truly normalizing glucose or merely slowing its upward drift.
Gaps in the data and what to watch next
Several questions remain open. The analyses were post-hoc, meaning they were not part of the original trial designs. Neither the DPPOS nor the Da Qing study was powered or randomized specifically to test whether prediabetes remission reduces cardiovascular events. That distinction matters because post-hoc analyses, even well-conducted ones, cannot fully rule out unmeasured confounding. People who returned to normal glucose levels may have differed from those who did not in ways the statistical models could not capture, such as overall fitness, dietary quality, or genetic predisposition.
The published data also do not fully detail how many participants achieved remission, how long they sustained it, or whether the cardiovascular benefit persisted after glucose levels drifted back up. Those details would help clinicians set realistic expectations. A person who briefly touches normal values for a year may not enjoy the same long-term protection as someone who maintains normoglycemia for a decade. Future analyses that track the “dose” of time spent in remission against cardiovascular outcomes could clarify how durable the effect needs to be.
Another gap involves how these findings translate to today’s broader and more diverse patient populations. Both trials enrolled people with impaired glucose tolerance under specific criteria, and standards of cardiovascular prevention have evolved since the 1980s and 1990s. Wider use of statins, blood pressure medications, and newer diabetes drugs with direct cardiovascular benefits could modify the absolute risk reductions seen in current practice, even if the relative impact of remission remains similar.
Researchers are likely to probe whether particular subgroups, such as older adults, people with existing heart disease, or those with obesity, gain more or less benefit from returning to normal blood sugar. They may also explore whether specific lifestyle patterns-such as higher levels of physical activity or particular dietary approaches-are more strongly associated with sustained remission and lower cardiovascular risk.
For now, the combined message from these long-running cohorts is straightforward: prediabetes is a critical window of opportunity. Intervening early enough to restore normal blood sugar appears to do more than postpone diabetes; it may dramatically reduce the likelihood of life-threatening heart problems. As clinicians and patients look for strategies that not only manage numbers but also prevent serious events, aiming for remission of prediabetes offers a tangible, evidence-backed target.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
